blind injection of Mepivacaine

ApprovedSmall molecule

CComplejo Hospitalario Universitario de Granada

blind injection of Mepivacaine is one of 4 small molecule programs targeting Morton Neuroma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Morton NeuromaActive, not recruiting

Morton NeuromaApproved

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Morton Neuroma

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

—2

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—3

blind injection of Mepivacaine

CComplejo Hospitalario Universitario de Granada

Approved

1 4

Medrol

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Morton Neuroma1 trial

Blind and Ultrasound Guided Injection in Morton Neuroma

Unknown status·—·Phase 4·NCT03046108·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for blind injection of Mepivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blind injection of Mepivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blind injection of Mepivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Complejo Hospitalario Universitario de Granada company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CComplejo Hospitalario Universitario de Granada

blind injection of Mepivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Morton Neuroma1 trial

References

Drug Info

Quick Facts

Related News